Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature

被引:22
作者
Rustemeyer, Jan [1 ,2 ]
Bremerich, Andreas [2 ]
机构
[1] Klinikum Bremen Mitte, Klin Mund Kiefer & Gesichtschirurg, D-28177 Bremen, Germany
[2] Ctr Bremen, Dept Craniomaxillofacial Surg, Ctr Clin, Bremen, Germany
关键词
Bisphosphonate; Osteonecrosis; Osteomyelitis; Jaw; Adverse effect; AVASCULAR NECROSIS; RISK-FACTORS; ZOLEDRONIC ACID; AMERICAN-SOCIETY; BONE-RESORPTION; CANCER-PATIENTS; ALENDRONATE; COMPLICATION; RECOMMENDATIONS; ANGIOGENESIS;
D O I
10.1007/s00784-009-0294-0
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Increasing application of bisphosphonates for therapy of osteopathies has led to reports of the severe associated adverse effects of osteonecrosis of the jaw (ONJ). We reviewed recent literature to assess several aspects of bisphosphonate-associated ONJ, and to provide healthcare professionals with an overview of treatment and preventive options. Literature databases were searched using keywords. Information of 54 articles were discussed and completed by additional literature. High-risk factors were application of nitrogen-containing bisphosphonates, teeth extractions, and ill-fitting dentures. Treatment included non-surgical options and radical surgery. Success and failure were described for all treatment options; further studies investigating long-term recovery and recurrence are warranted. Paying attention to effective prevention of ONJ before, during, and after treatment is essential.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 65 条
[2]   Bis-phossy jaws - High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw [J].
Abu-Id, Mario H. ;
Warnke, Patrick H. ;
Gottschalk, Joachim ;
Springer, Ingo ;
Wiltfang, Joerg ;
Acil, Yahya ;
Russ, Paul A. J. ;
Kreusch, Thomas .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2008, 36 (02) :95-103
[3]   Alendronate in the treatment of avascular necrosis of the hip [J].
Agarwala, S ;
Sule, A ;
Pai, BU ;
Joshi, VR .
RHEUMATOLOGY, 2002, 41 (03) :346-347
[4]   Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis [J].
Aguiar Bujanda, D. ;
Bohn Sarmiento, U. ;
Cabrera Suarez, M. A. ;
Aguiar Morales, J. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :556-560
[5]   Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment [J].
Allen, Matthew R. ;
Burr, David B. .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2008, 66 (05) :987-994
[6]   Systemic alendronate prevents resorption of necrotic bone during revascularization.: A bone chamber study in rats -: art. no. 19 [J].
Åstrand, J ;
Aspenberg, P .
BMC MUSCULOSKELETAL DISORDERS, 2002, 3 (1) :1-5
[7]   Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[8]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[9]   American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].
Berenson, JR ;
Hillner, BE ;
Kyle, RA ;
Anderson, K ;
Lipton, A ;
Yee, GC ;
Biermann, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736
[10]   Recommendations for zoledronic acid treatment of patients with bone metastases [J].
Berenson, JR .
ONCOLOGIST, 2005, 10 (01) :52-62